| Aug 8 |
GoodRx Holdings Non-GAAP EPS of $0.08 misses by $0.01, revenue of $200.6M in-line
|
| Aug 8 |
GoodRx Reports Second Quarter 2024 Results
|
| Aug 7 |
GoodRx Holdings Q2 2024 Earnings Preview
|
| Aug 6 |
Unveiling GoodRx (GDRX) Q2 Outlook: Wall Street Estimates for Key Metrics
|
| Jul 31 |
GoodRx Q2 Earnings Preview
|
| Jul 19 |
Boehringer Ingelheim offers Humira biosimilar at 92% discount
|
| Jul 18 |
GoodRx offers exclusive discount to biosimilar targeting AbbVie’s Humira
|
| Jul 18 |
GoodRx partners with Boehringer Ingelheim to discount Humira biosimilar
|
| Jul 18 |
Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira®
|
| Jul 17 |
ICLR vs. GDRX: Which Stock Is the Better Value Option?
|
